IL251141B - A method of predicting risk of recurrence of cancer - Google Patents
A method of predicting risk of recurrence of cancerInfo
- Publication number
- IL251141B IL251141B IL251141A IL25114117A IL251141B IL 251141 B IL251141 B IL 251141B IL 251141 A IL251141 A IL 251141A IL 25114117 A IL25114117 A IL 25114117A IL 251141 B IL251141 B IL 251141B
- Authority
- IL
- Israel
- Prior art keywords
- predicting
- risk
- cancer recurrence
- recurrence
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185673 | 2014-09-19 | ||
| PCT/EP2015/071524 WO2016042164A1 (en) | 2014-09-19 | 2015-09-18 | A method of predicting risk of recurrence of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL251141A0 IL251141A0 (en) | 2017-04-30 |
| IL251141B true IL251141B (en) | 2019-09-26 |
Family
ID=51589137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251141A IL251141B (en) | 2014-09-19 | 2017-03-14 | A method of predicting risk of recurrence of cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10557175B2 (enExample) |
| EP (1) | EP3194621B1 (enExample) |
| JP (1) | JP6730983B2 (enExample) |
| AU (1) | AU2015316711B2 (enExample) |
| CA (1) | CA2961725C (enExample) |
| ES (1) | ES2753625T3 (enExample) |
| IL (1) | IL251141B (enExample) |
| NZ (1) | NZ730124A (enExample) |
| WO (1) | WO2016042164A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6730983B2 (ja) | 2014-09-19 | 2020-07-29 | ザ プロボスト，フェローズ，ファウンデーション スカラーズ，アンド ジ アザー メンバーズ オブ ボード，オブ ザ カレッジ オブ ザ ホーリー アンド アンディブ．トリニティー オブ クイーン エリザベス，ニアー ダブリン | 癌の再発リスクを予測する方法 |
| CA3022377A1 (en) * | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
| CN106039312B (zh) * | 2016-05-25 | 2019-07-23 | 中山大学肿瘤防治中心 | Znf367基因在制备治疗乳腺癌药物、诊断及预后评估试剂中的应用 |
| GB201709417D0 (en) * | 2017-06-14 | 2017-07-26 | Inst Of Cancer Research: Royal Cancer Hospital | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer |
| USD875753S1 (en) * | 2018-03-06 | 2020-02-18 | Ventana Medical Systems, Inc. | Display screen or portion thereof with graphical user interface for biological slide scanning |
| WO2021072280A1 (en) * | 2019-10-09 | 2021-04-15 | The University Of North Carolina At Chapel Hill | Dna copy number alterations (cnas) to determine cancer phenotypes |
| EP4253567A1 (en) | 2022-03-31 | 2023-10-04 | OncoAssure Limited | A method of predicting risk of an aggressive or recurrent cancer |
| WO2025239278A1 (ja) * | 2024-05-16 | 2025-11-20 | 公益財団法人がん研究会 | リンパ管侵襲またはリンパ節転移の可能性を判定するための検査方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3170906B1 (en) * | 2003-06-24 | 2018-08-22 | Genomic Health, Inc. | Prediction of likelihood of cancer recurrence |
| US20080275652A1 (en) | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
| US7914988B1 (en) | 2006-03-31 | 2011-03-29 | Illumina, Inc. | Gene expression profiles to predict relapse of prostate cancer |
| WO2012030840A2 (en) * | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| EP2549399A1 (en) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
| WO2014066796A2 (en) * | 2012-10-25 | 2014-05-01 | Myriad Genetics, Inc. | Breast cancer prognosis signatures |
| EP2958999A4 (en) * | 2013-02-21 | 2016-10-19 | Myriad Genetics Inc | GENESIS FOR LUNG CANCER AWAKENING AND THERAPY SELECTION |
| JP6730983B2 (ja) * | 2014-09-19 | 2020-07-29 | ザ プロボスト，フェローズ，ファウンデーション スカラーズ，アンド ジ アザー メンバーズ オブ ボード，オブ ザ カレッジ オブ ザ ホーリー アンド アンディブ．トリニティー オブ クイーン エリザベス，ニアー ダブリン | 癌の再発リスクを予測する方法 |
-
2015
- 2015-09-18 JP JP2017515243A patent/JP6730983B2/ja active Active
- 2015-09-18 NZ NZ730124A patent/NZ730124A/en unknown
- 2015-09-18 EP EP15778623.7A patent/EP3194621B1/en active Active
- 2015-09-18 WO PCT/EP2015/071524 patent/WO2016042164A1/en not_active Ceased
- 2015-09-18 US US15/511,890 patent/US10557175B2/en active Active
- 2015-09-18 ES ES15778623T patent/ES2753625T3/es active Active
- 2015-09-18 CA CA2961725A patent/CA2961725C/en active Active
- 2015-09-18 AU AU2015316711A patent/AU2015316711B2/en active Active
-
2017
- 2017-03-14 IL IL251141A patent/IL251141B/en active IP Right Grant
-
2019
- 2019-12-20 US US16/722,041 patent/US20200157643A1/en not_active Abandoned
-
2022
- 2022-12-15 US US18/066,693 patent/US20240002947A1/en not_active Abandoned
-
2023
- 2023-08-07 US US18/366,436 patent/US12545961B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3194621B1 (en) | 2019-08-14 |
| US20240229147A1 (en) | 2024-07-11 |
| AU2015316711B2 (en) | 2021-10-21 |
| ES2753625T3 (es) | 2020-04-13 |
| US20180148788A1 (en) | 2018-05-31 |
| WO2016042164A1 (en) | 2016-03-24 |
| JP6730983B2 (ja) | 2020-07-29 |
| US12545961B2 (en) | 2026-02-10 |
| EP3194621A1 (en) | 2017-07-26 |
| US10557175B2 (en) | 2020-02-11 |
| AU2015316711A1 (en) | 2017-04-06 |
| CA2961725C (en) | 2023-04-04 |
| NZ730124A (en) | 2023-05-26 |
| CA2961725A1 (en) | 2016-03-24 |
| IL251141A0 (en) | 2017-04-30 |
| US20240002947A1 (en) | 2024-01-04 |
| US20200157643A1 (en) | 2020-05-21 |
| JP2017536085A (ja) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249981A0 (en) | Method | |
| HUE053145T2 (hu) | Kombinált tumor immunterápia | |
| DK3126390T3 (da) | Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi | |
| FI3198035T3 (fi) | Menetelmiä lääkevasteen ennustamiseksi | |
| LT3160952T (lt) | Histono demetilazės inhibitoriai | |
| DK3102263T3 (da) | Mekanisme til kappefjernelse | |
| IL247300A0 (en) | Biomarker directed multi-target immunotherapy | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3670826T3 (da) | Ekspanderbar brøndmetalrørform | |
| DK3140500T3 (da) | Brøndkompletteringssystem | |
| LT3233813T (lt) | Į oksatiaziną panašių junginių gavimo būdai | |
| DK3117216T3 (da) | Fremgangsmåde til detektering af en solid tumor-cancer | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| IL251141A0 (en) | A method for predicting the risk of cancer recurrence | |
| FR3029502B1 (fr) | Palonnier pour un aeronef | |
| DK3029959T3 (da) | Antenneenhed | |
| PL3201635T3 (pl) | Sposób przewidywania postępu raka za pomocą profilowania nanomechanicznego | |
| EP3310915A4 (en) | TUMOR IMMUNOTHERAPY | |
| DK3198034T3 (da) | Biomarkører for cervixcancer | |
| DE112015002984A5 (de) | Positioniereinheit | |
| IL252086A0 (en) | Novel methods | |
| DE102015100749A8 (de) | Drehtisch | |
| DK3032386T3 (da) | Optisk tastatur til eksplosive steder | |
| FI20140294A7 (fi) | Menetelmä fosfonaattien määrittämiseksi | |
| IL257514A (en) | Cancer detection method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |